antithymocyte globulin + daclizumab + etanercept + mycophenolate mofetil + sirolimus + tacrolimus

This is a combination immunosuppressive regimen consisting of six different immunomodulatory agents. The combination includes: - **Antithymocyte globulin (ATG)**: A polyclonal antibody preparation that targets T-cells, leading to T-lymphocyte cell death via complement-mediated cytotoxicity or apoptosis. - **Daclizumab**: A humanized monoclonal antibody that targets the IL-2 receptor. - **Etanercept**: A dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton tumor necrosis factor receptor linked to the Fc portion of human IgG1. It binds specifically to tumor necrosis factor (TNF) and modulates biological processes induced or regulated by TNF. - **Mycophenolate mofetil (MMF)**: An immunosuppressant that inhibits inosine monophosphate dehydrogenase, blocking T and B lymphocyte proliferation. - **Sirolimus**: An mTOR inhibitor that prevents activation of T cells and B cells by inhibiting their response to interleukin-2. - **Tacrolimus**: A calcineurin inhibitor that prevents T-cell activation. This combination regimen is likely used in the context of organ transplantation or severe autoimmune conditions to provide comprehensive immunosuppression through multiple complementary mechanisms.